LMR Partners’s ImmunityBio IBRX Stock Holding History

LMR Partners’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-47,402	Closed	-$144K	–	1495
2024 Q4	$121K	Buy	+47,402	New	+$197K	﹤0.01%	982
2019 Q4	–	Sell	-16,092	Closed	-$20K	–	474
2019 Q3	$20K	Hold	16,092	–	–	﹤0.01%	397
2019 Q2	$16K	Buy	+16,092	New	+$18.6K	﹤0.01%	407

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

LMR Partners's IBRX Position: Q1 2025 in Review

LMR Partners sold out of ImmunityBio (IBRX) in Q1 2025, closing a stake of 47,402 shares — an estimated $144K sold.

LMR Partners first reported a position in IBRX in Q2 2019 and held it in 3 quarters. The position peaked at $121K in Q4 2024. 210 funds tracked by Wall St. Rank hold IBRX as of Q1 2025.

LMR Partners reported no remaining ImmunityBio position as of Q1 2025 after selling out during the quarter.
LMR Partners sold 47,402 ImmunityBio shares in Q1 2025, an estimated $144K.
LMR Partners first reported a position in ImmunityBio in Q2 2019 and held it in 3 quarters.
LMR Partners's ImmunityBio position peaked at $121K in Q4 2024.
210 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.